Table 1

Effectiveness of anti-TNF therapies in treatment of Crohn's disease in three separate studies

Treatment Group	Infliximab 5 mg/kg	Etanercept 25 mg s.c.	CDP571 10 mg/kg
Placebo^1-a	4/24 (17%)	9/20 (45%)	15/56 (27%)
Anti-TNF treatment^1-a ^1-b	22/27 (81%)	9/23 (39%)	29/54 (54%)
No. to treat	1.6	N/A	3.7
Odds ratio (confidence interval)	20.8 (4.95, 87.4)	0.78 (0.23, 2.63)	3.17 (1.43, 7.03)

N/A, not applicable.
↵1-a Number of patients that showed a 70-point decrease in their Crohn's disease activity index/number of patients treated.
↵1-b Most efficacious dose evaluated in study.